Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 5/2019

01-08-2019 | Behçet's Disease | IM - REVIEW

Phenotypes in Behçet’s syndrome

Author: Emire Seyahi

Published in: Internal and Emergency Medicine | Issue 5/2019

Login to get access

Abstract

Behçet syndrome (BS) is a multi-systemic complex disorder with unknown etiology and a unique geographic distribution. It could not be possible to include it into specific classification schemes and it is certainly not a uniform disease. Several cluster and association studies revealed that it has been composed of multiple phenotypes ascribing the principal problem such as skin-mucosa, joint, eye, vascular, neurological and gastrointestinal involvement. Each phenotype has its own characteristic demographic and clinical features as such their management strategies and prognosis differ substantially. Actually, the concept of phenotyping has been well known for some time and is considered one of the basic elements of the still continuing debate whether to call this entity ‘disease’ or ‘syndrome’. Further supporting evidence comes from the observation of the geographical differences of disease expression. In this setting, BS resembles rather a construction made of several dynamic and interactive LEGO pieces of different shapes and colors. These pieces presenting phenotypes with their own disease mechanism have presumably different genetic determinants. The analysis of phenotyping could help us to identify this disorder and hence could contribute to find better ways of treatment.
Literature
1.
Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018 14:107–119 (Erratum in: Nat Rev Rheumatol. 2018 14 119)
2.
Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 82:60–76CrossRefPubMed
3.
Yurdakul S, Yazici Y (2010) Epidemiology of Behçet’s syndrome and regional differences in disease expression. In: Yazici Y, Yazici H (eds) Behçet’s Syndrome, 1st edn. Springer, New York, pp 35–52CrossRef
4.
Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, Tunç R, Urgancioğlu M, Dişçi R (2003) Prevalence of Behçet's disease in Istanbul. Turkey. Int J Dermatol. 42:803–806CrossRefPubMed
5.
Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, Lhote F, Ramanoelina J, Coste J, Guillevin L (2008) Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 58:3951–3959CrossRefPubMed
6.
7.
Yalçındaǧ FN, Özdal PC, Özyazgan Y, Batıoǧlu F, Tugal-Tutkun I (2018) Demographic and clinical characteristics of Uveitis in Turkey: the first national registry report. Ocul Immunol Inflamm. 26:17–26CrossRefPubMed
8.
Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M (1997) Budd-Chiari syndrome: a common complication of Behçet's disease. Am J Gastroenterol. 92:858–862PubMed
9.
Fabiani C, Vitale A, Orlando I, Sota J, Capozzoli M, Franceschini R, Galeazzi M, Tosi GM, Frediani B, Cantarini L (2017) Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study. Intern Emerg Med. 12:947–955CrossRefPubMed
10.
Senusi AA, Ola D, Mather J, Mather J, Fortune F. Behçet's syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status. Clin Exp Rheumatol. 2017;35 Suppl 108(6):43-50.
11.
Mehta P, Ambrose N, Haskard DO (2014) Work-related disability in Behçet's syndrome: a British case series. Clin Exp Rheumatol. 32(4 Suppl 84):S173–S174PubMed
12.
Sut N, Seyahi E, Yurdakul S, Senocak M, Yazici H (2007) A cost analysis of Behcet's syndrome in Turkey. Rheumatology (Oxford) 46:678–682CrossRef
13.
International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
14.
Barnes Colin G (2010) History and diagnosis. In: Yazici Y, Yazici H (eds) Behçet’s Syndrome, 1st edn. Springer, New York, pp 7–34CrossRef
15.
Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y (2011) Behçet disease: evolution of clinical manifestations. Medicine (Baltimore). 90:125–132CrossRefPubMed
16.
Yazici H, Ugurlu S, Seyahi E (2012) Behçet syndrome: is it one condition? Clin Rev Allergy Immunol. 43:275–280CrossRefPubMed
17.
Gül A (2015) Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Semin Immunopathol. 37:413–418CrossRefPubMed
18.
Gül A (2014) Genetics of Behçet's disease: lessons learned from genomewide association studies. Curr Opin Rheumatol. 26:56–63CrossRefPubMed
19.
Direskeneli H, Saruhan-Direskeneli S (2010) Disease mechanisms. In: Yazici Y, Yazici H (eds) Behçet’s syndrome, 1st edn. Springer, New York, pp 243–264CrossRef
20.
Oran M, Hatemi G, Tasli L, Garip F, Kadioglu P, Mat C, Yazici H (2008) Behçet's syndrome is not associated with vitiligo. Clin Exp Rheumatol. 26(Suppl 50):S107–S109PubMed
21.
Seyahi E, Ugurlu S, Cumali R, Balci H, Ozdemir O, Melikoglu M, Hatemi G, Fresko I, Hamuryudan V, Yurdakul S, Yazici H (2008) Atherosclerosis in Behçet's syndrome. Semin Arthritis Rheum. 38:1–12CrossRefPubMed
22.
Yazici H, Fresko I (2005) Behçet's disease and other autoinflammatory conditions: what's in a name? Clin Exp Rheumatol. 23(4 Suppl 38):S1–2PubMed
23.
Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Di Scala G, Sota J, Orlando I, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2018) The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. Ocul Immunol Inflamm. 27:1–7CrossRef
24.
Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 36(1):191–197CrossRefPubMed
25.
Grayson PC, Yazici Y, Merideth M, Sen HN, Davis M, Novakovich E, Joyal E, Goldbach-Mansky R, Sibley CH (2017) Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study. Arthritis Res Ther. 19(1):69CrossRefPubMedPubMedCentral
26.
Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gül A (2018) Use of Gevokizumab in patients with behçet's disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 26(7):1023–1033CrossRefPubMed
27.
Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B, Bertoldi I, Punzi L, Galeazzi M, Cimaz R (2015) Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol. 34(7):1293–1301CrossRefPubMed
28.
Melikoglu M, Kural-Seyahi E, Tascilar K, Yazici H (2008) The unique features of vasculitis in Behçet's syndrome. Clin Rev Allergy Immunol. 35:40–46CrossRefPubMed
29.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65:1–11CrossRefPubMed
30.
Ishido T, Horita N, Takeuchi M, Kawagoe T, Shibuya E, Yamane T, Hayashi T, Meguro A, Ishido M, Minegishi K, Yoshimi R, Kirino Y, Kato S, Arimoto J, Ishigatsubo Y, Takeno M, Kurosawa M, Kaneko T, Mizuki N (2017) Clinical manifestations of Behçet's disease depending on sex and age: results from Japanese nationwide registration. Rheumatology (Oxford) 56:1918–1927CrossRef
31.
Chu JH, Hersh CP, Castaldi PJ, Cho MH, Raby BA, Laird N, Bowler R, Rennard S, Loscalzo J, Quackenbush J, Silverman EK (2014) Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. BMC Syst Biol. 8:78CrossRefPubMedPubMedCentral
32.
Brito-Zerón P, Retamozo S, Ramos-Casals M (2018) Phenotyping Sjögren's syndrome: towards a personalised management of the disease. Clin Exp Rheumatol. 36(Suppl 112):198–209PubMed
33.
Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H (2001) Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis. 60:1074–1076CrossRefPubMedPubMedCentral
34.
Tunc R, Keyman E, Melikoglu M, Fresko I, Yazici H (2002) Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. J Rheumatol. 29:2393–2396PubMed
35.
Tunc R, Saip S, Siva A, Yazici H (2004) Cerebral venous thrombosis is associated with major vessel disease in BS's syndrome. Ann Rheum Dis. 63:1693–1694CrossRefPubMedPubMedCentral
36.
Karaca M, Hatemi G, Sut N, Yazici H (2012) The papulopustular lesion/arthritis cluster of Behçet's syndrome also clusters in families. Rheumatology (Oxford) 51:1053–1060CrossRef
37.
Yazici H. The lumps and bumps of Behcet's syndrome. Autoimmun Rev 2004; Suppl 1:S53-4.
38.
39.
Hatemi G, Fresko I, Tascilar K, Yazici H (2008) Enthesopathy is increased among Behçet’s syndrome patients with acne and arthritis: an ultrasonographic study. Arthritis Rheum 58:1539–1545CrossRefPubMed
40.
Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H (2014) Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford) 53:2018–2022CrossRef
41.
Seyahi E, Caglar E, Ugurlu S, Kantarci F, Hamuryudan V, Sonsuz A, Melikoglu M, Yurdakul S, Yazici H (2015) An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center. Semin Arthritis Rheum. 44:602–609CrossRefPubMed
42.
Suzuki T, Horita N, Takeuchi M et al (2018) Clinical features of early-stage possible Behçet's disease patients with a variant-type major organ involvement in Japan. Mod Rheumatol. 28:1–18CrossRef
43.
Kurosawa M, Takeno Y, Kirino Y, Soejima N, Mizuki M. Subgroup classification of Behçet's disease using clinical information: analysis of a clinical database of patients receiving financial aid for treatment. ISBD conference 2018, Rotterdam.
44.
Krause I, Leibovici L, Guedj D, Molad Y, Uziel Y, Weinberger A (1999) Disease patterns of patients with Behçet's disease demonstrated by factor analysis. Clin Exp Rheumatol. 17:347–350PubMed
45.
Arida A, Vaiopoulos G, Markomichelakis N, Kaklamanis P, Sfikakis PP. Are clusters of patients with distinct clinical expression present in Behçet's disease? Clin Exp Rheumatol. 2009;27(Suppl 53):S48–51.
46.
Bitik B, Tufan A, Sahin K, Sucullu Karadag Y, Can Sandikci S, Mercan R, Ak F, Karaaslan Y, Ozturk MA, Goker B, Haznedaroglu S (2016) The association between the parenchymal neurological involvement and posterior uveitis in Behçet's syndrome. Clin Exp Rheumatol. 34(6 Suppl 102):82–85PubMed
47.
Suwa A, Horita N, Ishido T, Takeuchi M, Kawagoe T, Shibuya E, Yamane T, Hayashi T, Meguro A, Ishido M, Minegishi K, Yoshimi R, Kirino Y, Kato S, Arimoto J, Fukumoto T, Ishigatsubo Y, Kurosawa M, Kaneko T, Takeno M, Mizuki N (2018) The ocular involvement did not accompany with the genital ulcer or the gastrointestinal symptoms at the early stage of Behçet's disease. Mod Rheumatol. 15:1–6
48.
Hussein MA, Eissa IM, Dahab AA (2018) Vision-Threatening Behcet's Disease: Severity of Ocular Involvement Predictors. J Ophthalmol. 2018:9518065PubMedPubMedCentral
49.
Mat C, Yurdakul S, Sevim A, Özyazgan Y, Tüzün Y (2013) Behçet's syndrome: facts and controversies. Clin Dermatol. 31:352–361CrossRefPubMed
50.
Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, Can M, Oner SY, Inanc N, Atagunduz P, Ergun T, Direskeneli H (2014) Unmet need in Behcet's disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 33:1773–1776CrossRefPubMed
51.
Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H (2012) Frequent oral ulceration during early disease may predict a severe disease course in males with Behçet's syndrome. Clin Exp Rheumatol. 30(3 Suppl 72):S32–S34PubMed
52.
Volle G, Fraison JB, Gobert D, Goulenok T, Dhote R, Fain O, Gonzalez-Chiappe S, Lhote F, Papo T, Thuillier A, Rivière S, Mahr A (2017) Dietary and nondietary triggers of oral ulcer recurrences in Behçet's disease. Arthritis Care Res (Hoboken). 69:1429–1436CrossRefPubMed
53.
Soy M, Erken E, Konca K, Ozbek S (2000) Smoking and Behçet's disease. Clin Rheumatol. 19:508–509CrossRefPubMed
54.
Guzelant G, Ozguler Y, Esatoglu SN, Karatemiz G, Ozdogan H, Yurdakul S, Yazici H, Seyahi E (2017) Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. Clin Exp Rheumatol. 35(6):95–99PubMed
55.
Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, Direskeneli H (2004) Oral health is impaired in Behçet's disease and is associated with disease severity. Rheumatology (Oxford) 43:1028–1033CrossRef
56.
Mat C, Göksugur N, Engin B et al (2006) The frequency of scarring after genital ulcers in Behçet’s syndrome: a prospective study. Int J Dermatol 45:554–556CrossRefPubMed
57.
Kutlubay Z, Mat CM, Aydin Ö, Demirkesen C, Calay Ö, Engin B, Tüzün Y, Yazici H (2015) Histopathological and clinical evaluation of papulopustular lesions in Behçet's disease. Clin Exp Rheumatol. 33(6 Suppl 94):S101–S106PubMed
58.
Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, Altas K, Yazici H (2004) The pustular skin lesions in Behcet's syndrome are not sterile. Ann Rheum Dis. 63:1450–1452CrossRefPubMedPubMedCentral
59.
Demirkesen C, Tüzüner N, Mat C, Senocak M, Büyükbabani N, Tüzün Y, Yazici H (2001) Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol. 116(3):341–346CrossRefPubMed
60.
61.
Yurdakul S, Hatemi G (2010) Locomotor System Disease in Behçet’s Syndrome. In: Yazici Y, Yazici H (eds) Behçet’s syndrome, 1st edn. Springer, New York, pp 149–164CrossRef
62.
Seyahi E (2016) Behçet's disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 30:279–295CrossRefPubMed
63.
Schirmer M, Calamia KT, O'Duffy JD (1999) Is there a place for large vessel disease in the diagnostic criteria of Behçet's disease? J Rheumatol. 26:2511–2512PubMed
64.
Uzun O, Akpolat T, Erkan L (2005) Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest 127:2243–2253CrossRefPubMed
65.
Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, Yurdakul S, Tuzun H, Oz B, Yazici H (2012) Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore). 91:35–48CrossRefPubMed
66.
Erkan D, Yazici Y, Sanders A, Trost D, Yazici H (2004) Is Hughes-Stovin syndrome Behçet's disease? Clin Exp Rheumatol. 22(4 Suppl 34):S64–S68PubMed
67.
Bennji SM, du Preez L, Griffith-Richards S, Smit DP, Rigby J, Koegelenberg CFN, Irusen EM, Allwood BW (2017) Recurrent pulmonary aneurysms: Hughes–Stovin syndrome on the spectrum of Behçet disease. Chest 152:e99–e103CrossRefPubMed
68.
Seyahi E, Yazici H (2016) To anticoagulate or not to anticoagulate vascular thrombosis in Behçet's syndrome: an enduring question. Clin Exp Rheumatol. 34(Suppl 95):S3–S4PubMed
69.
Leiba M, Seligsohn U, Sidi Y et al (2004) Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 63:1445–1449CrossRefPubMedPubMedCentral
70.
Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, Koskas F, Desseaux K, Cacoub P, Saadoun D (2012) Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum. 64:2753–2760CrossRefPubMed
71.
Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, Cacoub P (2010) Mortality in Behçet's disease. Arthritis Rheum. 62:2806–2812CrossRefPubMed
72.
Desbois AC, Rautou PE, Biard L, Belmatoug N, Wechsler B, Resche-Rigon M, Zarrouk V, Fantin B, de Chambrun MP, Cacoub P, Valla D, Saadoun D, Plessier A (2014) Behcet's disease in Budd–Chiari syndrome. Orphanet J Rare Dis. 9:104CrossRefPubMedPubMedCentral
73.
Ugurlu S, Seyahi E, Oktay V, Kantarci F, Tuzun H, Yigit Z, Arslan C, Yazici H (2015) Venous claudication in Behçet's disease. J Vasc Surg. 62(3):698–703.e1CrossRefPubMed
74.
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed
75.
Tugal-Tutkun I, Gupta V, Cunningham ET (2013) Differential diagnosis of behçet uveitis. Ocul Immunol Inflamm. 21:337–350CrossRefPubMed
76.
Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, Usui M (2005) Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 243:1147–1152CrossRefPubMed
77.
Tugal-Tutkun I, Onal S, Ozyazgan Y, Soylu M, Akman M (2014) Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behçet uveitis. Ocul Immunol Inflamm. 22:461–468CrossRefPubMed
78.
Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients The Neuro-Behcet Study Group. Brain 122:2171–2182CrossRefPubMed
79.
Siva A, Kantarci OH, Saip S et al (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurology 248:95–103CrossRef
80.
Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D, Piette JC, Drier A, Dormont D, Cacoub P, Saadoun D. Long-term outcome of neuro-Behçet's disease. Arthritis Rheumatol. 2014;66:1306-14.
81.
Cheon JH, Kim WH (2015) An update on the diagnosis, treatment, and prognosis of intestinal Behçet's disease. Curr Opin Rheumatol. 27:24–31CrossRefPubMed
82.
Hatemi I, Hatemi G, Çelik AF (2018) Gastrointestinal Involvement in Behçet Disease. Rheum Dis Clin North Am. 44:45–64CrossRefPubMed
83.
Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF (2016) Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet's syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 95:e3348CrossRefPubMedPubMedCentral
84.
Hatemi I, Hatemi G, Celik AF, Melikoglu M, Arzuhal N, Mat C, Ozyazgan Y, Yazici H (2008) Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease. Clin Exp Rheumatol. 26(4 Suppl 50):S91–S95PubMed
85.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693–1700CrossRefPubMed
86.
Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787CrossRefPubMed
87.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 373:2534–2548CrossRefPubMed
88.
Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y (2011) Characteristics of vascular involvement in Behçet's disease in Japan: a retrospective cohort study. Clin Exp Rheumatol. 29(4 Suppl 67):S47–53PubMed
89.
Celik S, Yazici Y, Sut N, Yazici H (2015) Pulmonary artery aneurysms in Behçet's syndrome: a review of the literature with emphasis on geographical differences. Clin Exp Rheumatol. 33(6 Suppl 94):S54–S59PubMed
90.
Han JK, Kim HK, Kim YJ, Cho GY, Kim MA, Sohn DW, Park YB (2009) Behçet's disease as a frequently unrecognized cause of aortic regurgitation: suggestive and misleading echocardiography findings. J Am Soc Echocardiogr. 22:1269–1274CrossRefPubMed
91.
Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, Weinberger A (2001) Behçet's disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol. 28(5):1033–1036PubMed
92.
Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, Hamzaoui K. Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol. 2007;25(Suppl 45):S58–64.
93.
Leccese P, Yazici Y, Olivieri I (2017) Behcet's syndrome in nonendemic regions. Curr Opin Rheumatol. 29:12–16CrossRefPubMed
94.
Savey L, Resche-Rigon M, Wechsler B, Comarmond C, Piette JC, Cacoub P, Saadoun D (2014) Ethnicity and association with disease manifestations and mortality in Behçet's disease. Orphanet J Rare Dis. 9:42CrossRefPubMedPubMedCentral
95.
Zouboulis CC, Kotter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, Keitel W, Stadler R, Wollina U, Proksch E, Söhnchen R, Weber H, Gollnick HP, Hölzle E, Fritz K, Licht T, Orfanos CE (1997) Epidemiological features of Adamantiades Behcet's disease in Germany and in Europe. Yonsei Med J 38:411–422CrossRefPubMed
96.
Mok CC, Cheung TC, Ho CT, Lee KW, Lau CS, Wong RW (2002) Behçet's disease in southern Chinese patients. J Rheumatol. 29:1689–1693PubMed
97.
Muhaya M, Lightman S, Ikeda E, Mochizuki M, Shaer B, McCluskey P, Towler HM (2000) Behçet's disease in Japan and in Great Britain: a comparative study. Ocul Immunol Inflamm. 8:141–148CrossRefPubMed
98.
Rozenbaum M, Boulman N, Slobodin G, Zisman D, Mader R, Yankevitch A, Weinberger A, Rosner I (2007) Behcet disease in adult Druzes in north Israel: the influence of ethnic origin on disease expression and severity. J Clin Rheumatol. 13:124–127CrossRefPubMed
99.
Sibley C, Yazici Y, Tascilar K, Khan N, Bata Y, Yazici H, Goldbach-Mansky R, Hatemi G (2014) Behçet syndrome manifestations and activity in the United States versus Turkey—a cross-sectional cohort comparison. J Rheumatol. 41:1379–1384CrossRefPubMedPubMedCentral
100.
Mohammad A, Mandl T, Sturfelt G, Segelmark M (2013) Incidence, prevalence and clinical characteristics of Behcet's disease in southern Sweden. Rheumatology (Oxford) 52:304–310CrossRef
101.
Kötter I, Vonthein R, Müller CA, Günaydin I, Zierhut M, Stübiger N (2004) Behçet's disease in patients of German and Turkish origin living in Germany: a comparative analysis. J Rheumatol. 31:133–139PubMed
102.
Kappen JH, van Dijk EH, Baak-Dijkstra M, van Daele PL, Lam-Tse WK, van Hagen PM, van Laar JA (2015) Behçet's disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth J Med. 73:471–477PubMed
Metadata
Title
Phenotypes in Behçet’s syndrome
Author
Emire Seyahi
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 5/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02046-y

Other articles of this Issue 5/2019

Internal and Emergency Medicine 5/2019 Go to the issue

Editor’s Page

Behçet’s syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments

IM - ORIGINAL

Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis

IM - ORIGINAL

Does illness perception associate with disease symptoms in Behçet’s disease?

IM - CASE RECORD

Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis

Im-Point of View

Handling shock in idiopathic systemic capillary leak syndrome (Clarkson’s disease): less is more

IM - REVIEW

Update on the treatment of Behçet’s syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits